Tadashi Hirose
Direktor/Vorstandsmitglied bei Prolexys Pharmaceuticals, Inc.
Profil
Tadashi Hirose is a Director of Prolexys Pharmaceuticals, Inc. He is President of the Corporate Ventures Catalyst Division for Hitachi America Ltd.
and President of the Corporate Ventures Capital Office of Hitachi Ltd.
Prior to his current position at Hitachi, he was Senior Researcher of Systems Development Laboratory, Department Manager of the Information Systems Group, the Information and Telecom Systems Group, and Senior Vice President of Hitachi Computer America Ltd.
He joined Hitachi in April 1975.
Mr. Hirose received a BS degree in Instrumental and System Control Engineering and an MS degree in Mathematical Programming from Keio University in Japan.
Aktive Positionen von Tadashi Hirose
| Unternehmen | Position | Beginn |
|---|---|---|
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Tadashi Hirose
| Unternehmen | Position | Ende |
|---|---|---|
| HITACHI, LTD. | Corporate Officer/Principal | - |
Ausbildung von Tadashi Hirose
| Keio University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HITACHI, LTD. | Producer Manufacturing |
| Private Unternehmen | 1 |
|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
